Spike Protein News and Research

RSS

Application of various nanoparticle-capsulated siRNA as therapeutics for SARS-CoV-2 infection

In a review published in the International Journal of Molecular Sciences, researchers have been reviewing the use of siRNAs to target coronaviruses.

25 Feb 2022

Study identifies higher infection rate and lower disease severity during Omicron wave in US

Scientists from the Case Western Reserve University, USA, have recently conducted a study in collaboration with the National Institutes of Health, USA, to investigate the incidence rates and disease severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States before and after the emergence of omicron variant.

24 Feb 2022

Serological responses to heterologous COVID-19 mRNA vaccination in older individuals

Researchers assess the serological response to a real-world COVID-19 vaccination strategy in older individuals who resided in long-term care facilities.

24 Feb 2022

Should SARS-CoV-2 Omicron be considered a serotype?

A recent article provides evidence for and against the hypothesis of SARS-CoV-2 serotypes.

24 Feb 2022

A comparison of COVID-19 vaccines by neutralizing antibody potency

Researchers use an international standardized assessment method to compare the efficacy of antibody responses to the major COVID-19 vaccines.

24 Feb 2022

Study finds two doses of COVID-19 vaccines were insufficient to neutralize the SARS-CoV-2 Omicron variant

Researchers determined the neutralization potency of sera from people vaccinated with BNT162b2, mRNA-1273, or ChAdOx1 against the novel SARS-CoV-2 Omicron variant.

24 Feb 2022

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

A recent study assessed the persistence of SARS-CoV-2 antibody five and 12 months post-infection in non-vaccinated patients.

24 Feb 2022

Omicron BA. 2 reinfections can occur shortly following BA.1 infection

Researchers investigated the probability of Omicron BA.2 reinfections following SARS-CoV-2 Omicron BA.1 initial infection by whole genomic sequencing in the period of dominance of these subvariants in Denmark.

24 Feb 2022

Pulmonary dysfunction in pediatric patients after acute COVID-19 infection

A recent study examined the pulmonary dysfunction persistent in pediatric populations post-acute COVID-19 infection.

24 Feb 2022

First reported case of a cat infected with SARS-CoV-2 Delta AY.3 variant

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is hurting our loved ones — even those that walk on four legs. Researchers from the University of Pennsylvania documented the recovery of an 11-year old indoor housecat living in Delaware who first presented to the veterinary hospital after experiencing distressing gastrointestinal symptoms.

23 Feb 2022

Study on Omicron related mortality in cancer patients during recent COVID wave

A recent pre-proof study published in the journal Cancer Cell assessed the CFR of cancer patients during the third wave of the coronavirus disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 Omicron variant.

23 Feb 2022

Outcomes of phase 3 clinical trial of CVO PLUS CURATIF capsules for COVID-19 treatment

A phase 3 randomized clinical trial has recently been conducted to investigate the efficacy of a capsule formulation in treating mild-to-moderate COVID-19 patients.

23 Feb 2022

hAELVi cell infection model mimics SARS-CoV-2 Omicron infection in lower respiratory tract of humans

In a recent study posted to the Research Square* preprint server, which is under consideration at Scientific Reports, a team of researchers developed a novel human Alveolar Epithelial Lentivirus immortalized (hAELVi) cell infection model to estimate the replication potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory viruses in the lower respiratory tract of humans.

23 Feb 2022

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses.

22 Feb 2022

Exploring the potential of mosaic RBD nanoparticles to fight SARS-CoV-2

Researchers explore the potential of mosaic receptor-binding domain nanoparticles in protective immunity against SARS-CoV-2

22 Feb 2022

REGEN-COV antibody combination to prevent COVID-19 severity

A new study assessed the effectiveness of REGEN-COV, a combination of casirivimab and imdevimab monoclonal antibodies, in the prevention of COVID-19 disease severity.

22 Feb 2022

Lung microbiome alterations and secondary-infections in lethal COVID-19

Researchers examined how an interplay of host and microbial factors weakened immunity leading to secondary infections in COVID-19-infected individuals.

22 Feb 2022

Study suggests anti-SARS-CoV-2 antibodies may persist lifelong post-infection

Researchers attempted to delineate the duration and stability of anti-SARS-CoV-2 antibodies in patients who had recovered from the COVID-19 infection.

22 Feb 2022

Time-based sensitivity of COVID-19 serological testing

In a recent study under consideration at Scientific Reports and posted to the Research Square* preprint server, researchers evaluated the impact of time on the sensitivity of four severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological assays using samples from the coronavirus disease 2019 (COVID-19) staff testing of antibody responses study(Co-Stars) in the United Kingdom (UK).

22 Feb 2022

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Researchers identify 87G7, a SARS-CoV-2 neutralizing human monoclonal antibody with remarkable broad-spectrum neutralization and protection efficacy.

21 Feb 2022

Spike Protein News and Research

Application of various nanoparticle-capsulated siRNA as therapeutics for SARS-CoV-2 infection

Study identifies higher infection rate and lower disease severity during Omicron wave in US

Serological responses to heterologous COVID-19 mRNA vaccination in older individuals

Should SARS-CoV-2 Omicron be considered a serotype?

A comparison of COVID-19 vaccines by neutralizing antibody potency

Study finds two doses of COVID-19 vaccines were insufficient to neutralize the SARS-CoV-2 Omicron variant

Antibody levels against SARS-CoV-2 spike protein up to 12 months after COVID-19 infection in non-vaccinated individuals

Omicron BA. 2 reinfections can occur shortly following BA.1 infection

Pulmonary dysfunction in pediatric patients after acute COVID-19 infection

First reported case of a cat infected with SARS-CoV-2 Delta AY.3 variant

Study on Omicron related mortality in cancer patients during recent COVID wave

Outcomes of phase 3 clinical trial of CVO PLUS CURATIF capsules for COVID-19 treatment

hAELVi cell infection model mimics SARS-CoV-2 Omicron infection in lower respiratory tract of humans

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

Exploring the potential of mosaic RBD nanoparticles to fight SARS-CoV-2

REGEN-COV antibody combination to prevent COVID-19 severity

Lung microbiome alterations and secondary-infections in lethal COVID-19

Study suggests anti-SARS-CoV-2 antibodies may persist lifelong post-infection

Time-based sensitivity of COVID-19 serological testing

Novel ACE2-blocking antibody protects against all SARS-CoV-2 VOCs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News